Theraloc (nimotuzumab) for high grade glioma: the manufacturer withdrawed its marketing application

EMEA press release about the marketing authorization withdrawal for the monoclonal antibody nimotuzumab (Theraloc): Oncoscience AG withdraws its application for Theraloc (nimotuzumab) The European Medicines Agency (EMEA) has been formally notified by Oncoscience AG of its┬ádecision to withdraw its application for a centralised marketing authorisation for the medicine┬áTheraloc (nimotuzumab), 5 mg/ml concentrate for solution for […]